Dutch licensor sells its shares in Canopy Growth Corp
Bedrocan International, a well-known, global active licensor for the production of fully standardised pharmaceutical grade cannabis, recently sold its remaining shareholdings in Canada based Canopy Growth Corporation (CGC). Herewith the licensor of the global Bedrocan brand underlines its medical disposition in Canada. Bedrocan International distances itself from Canopy Growth's clearly expressed future strategy, aiming for large scale production of cannabis for recreational use under the expected legalization in Canada by the Trudeau government. Bedrocan International remains fully committed to support and upgrade the Canadian Bedrocan facility acting solely under the name Bedrocan Canada to the highest technical and pharmaceutical standards for it to meet increasing demand and the need to be GMP-compliant. Thus serving the needs of Canadian patients and their physicians.
It is Bedrocan International 's strong belief that there should be a clear distinction between medicinal and recreational use of cannabis and that patient needs for safe and consistent cannabis is a priority. Bedrocan International's founder and chairman of the board, Tjalling Erkelens is convinced that this can be achieved: "Cannabis can and should go through the drug approval process. Fully standardised medicinal cannabis is the foundation on which such approval can be achieved."
Bedrocan Canada Inc. (wholly owned by CGC) is a licensee of Bedrocan's brand, cultivation methods and processing technique. CGC doesn't produce or sell medicinal cannabis. Besides Bedrocan Canada, CGC also owns Tweed Inc and Tweed Farms. Bedrocan (International)'s chairman of the board Tjalling Erkelens: "Bedrocan is increasingly recognised as the leading authority in the medicinal use of cannabis worldwide. Cannabis to us is not a lifestyle product. It is a medicine, that should be effective, safe and affordable for any patient. We at Bedrocan International emphasize this in our mission and vision."
It is the ongoing intention of Bedrocan International to serve patients in Canada with medicinal cannabis only of the highest quality. With this defined position, along with a renewed production facility, Bedrocan International looks forward to further fulfilling its mission and vision in Canada with Bedrocan Canada as its exclusive licensee inCanada.
